Antibodies and methods for making and using them
The invention provides antibodies, including chimeric human antibodies, recombinant antibodies, synthetic antibodies, and the nucleic acids encoding them, and methods for making and using these immunoglobulins. The invention provides recombinant and synthetic polypeptide and nucleic acid embodiments of these polypeptides and/or antibodies. The invention also provides polypeptides comprising, or consisting of, consensus human framework regions, or “Independently Consensused Frameworks (ICFs)”, nucleic acids encoding them, and libraries and kits comprising these ICFs and/or antibodies of the invention, individually and in combinatorial libraries and combinations.
1. An antibody or antigen-binding fragment thereof comprising at least one variable region having a combination of:
(1) light chain BD22084 (SEQ ID NO:225) and heavy chain BD20332 (SEQ ID NO:138);
(2) light chain BD22085 (SEQ ID NO:232) and heavy chain BD20335 (SEQ ID NO:143);
(3) light chain BD22086 (SEQ ID NO:227) and heavy chain BD20335 SEQ ID NO:143);
(4) light chain BD22088 (SEQ ID NO:229) and heavy chain BD20337 (SEQ ID NO:148);
(5) light chain BD22087 (SEQ ID NO:240) and heavy chain BD20335 (SEQ ID NO:143);
(6) light chain BD22089 (SEQ ID NO:243) and heavy chain BD20335 (SEQ ID NO:143);
(7) light chain BD22090 (SEQ ID NO:234) and heavy chain BD20337 (SEQ ID NO:148);
(8) light chain BD22095 (SEQ ID NO:244) and heavy chain BD20337 (SEQ ID NO:148);
(9) light chain BD22091 (SEQ ID NO:242) and heavy chain BD20337 (SEQ ID NO:148);
(10) light chain BD22108 (SEQ ID NO:230) and heavy chain BD20337 (SEQ ID NO:148);
(11) light chain BD22092 (SEQ ID NO:235) and heavy chain BD20338 (SEQ ID NO:149);
(12) light chain BD22094 (SEQ ID NO:231) and heavy chain BD20337 (SEQ NO: 148);
(13) light chain BD22096 (SEQ ID NO:241) and heavy chain BD20337 (SEQ ID NO:148);
(14) light chain BD22092 (SEQ ID NO:235) and heavy chain BD20337 (SEQ ID NO:148);
(15) light chain BD22102 (SEQ ID NO:248) and heavy chain BD20337 (SEQ ID NO: 148);
(16) light chain BD22097 (SEQ ID NO:246) and heavy chain BD20335 (SEQ ID NO:143);
(17) light chain BD22104 (SEQ ID NO:239) and heavy chain BD20337 SEQ ID NO:148);
(18) light chain BD22085 (SEQ ID NO:232) and heavy chain BD20339 (SEQ ID NO:150);
(19) light chain BD22107 (SEQ ID NO:226) and heavy chain BD20339 (SEQ ID NO: 150);
(20) light chain BD22100 (SEQ ID NO:236) and heavy chain BD20335 (SEQ ID NO:143);
(21) light chain BD22103 (SEQ ID NO:228) and heavy chain BD20337 SEQ ID NO:148);
(22) light chain BD22105 (SEQ ID NO:237) and heavy chain BD20337 (SEQ ID NO:148);
(23) light chain BD22101 (SEQ ID NO:247) and heavy chain BD20335 (SEQ ID NO:143);
(24) light chain BD22106 (SEQ ID NO:245) and heavy chain BD20333 (SEQ ID NO:142);
(25) light chain BD22108 (SEQ ID NO:230) and heavy chain BD20338 (SEQ ID NO:149);
(26) light chain BD22109 (SEQ ID NO:233) and heavy chain BD20341 (SEQ ID NO:154); or
(27) light chain BD22111 (SEQ ID NO:238) and heavy chain BD20336 (SEQ ID NO:144).
2. The antigen binding antibody fragment of claim 1 , wherein the antibody fragment is an Fab fragment, an Fab′ fragment, an F(ab′), fragment, a single-chain antibody, an Fv fragment, an scFv fragment, an antibody mimetic, an Fd fragment, or an Fd′ fragment.
3. The antigen binding antibody fragment of claim 2 , wherein the antibody fragment is fused to an Fc.
4. A recombinant, synthetic or isolated antibody having a structure comprising at least one variable region combination of claim 1 .
5. A chimeric antibody or antigen binding fragment thereof comprising at least one variable region combination of claim 1 .
6. A chimeric antigen binding antibody fragment of claim 5 , wherein the chimeric antibody fragment is a chimeric Fab, a chimeric Fab′, a chimeric F(ab′) 2 , a chimeric single-chain antibody, a chimeric Fv, a chimeric scFv, an antibody mimetic, a chimeric Fd, or a chimeric Fd′.
7. A pharmaceutical composition or formulation comprising:
(a) an antibody or antigen binding fragment thereof of claim 1 .
8. The pharmaceutical composition or formulation of claim 7 , further comprising a pharmaceutically acceptable carrier or excipient.